NGM · Biotechnology

Vera Therapeutics, Inc. (VERA) Stock

$29.81 +0.27% NGM: VERA Healthcare

Valuation

MetricValue
Price$29.81
Market Cap$2.14B
P/E Ratio-5.58
P/B Ratio5.76
P/S Ratio0.00
EPS (TTM)$-5.54
52-Week High$56.05
52-Week Low$23.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-84.13%
ROA-75.40%
ROCE-85.78%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.18
Current Ratio13.64

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-34.0M$-91.0M$-102.0M$-167.0M$-315.0M
Net Profit$-33.0M$-89.0M$-96.0M$-152.0M$-300.0M
EPS$-2.43$-3.35$-2.25$-2.75$-4.66
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$84.0M$131.0M$176.0M$656.0M$735.0M
Total Liabilities$14.0M$55.0M$74.0M$79.0M$130.0M
Cash$80.0M$43.0M$46.0M$93.0M$355.0M
Borrowings$5.0M$31.0M$54.0M$55.0M$77.0M

Latest News

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch MarketBeat · Jul 11, 2026 Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026 Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)? Simply Wall St. · Jul 10, 2026 Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval Simply Wall St. · Jul 10, 2026 Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run Simply Wall St. · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-68.0M$-92.0M$-135.0M$-241.0M
Investing Cash Flow$-4.0M$-71.0M$-39.0M$-426.0M$194.0M
Financing Cash Flow$-2.0M$-4.0M$-6.0M$-26.0M$-22.0M
Net Cash Flow$26.0M$-36.0M$2.0M$47.0M$262.0M
Free Cash Flow$-24.0M$-68.0M$-92.0M$-136.0M$-242.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.14
EV / EBITDA-6.08
FCF Yield-14.45%
Quick Ratio10.92
Interest Coverage-36.93
Return 1Y61.75%
Return 3Y115.77%
Return 5Y104.86%

Ownership

Insiders Held0.78%
Institutions Held110.70%
Institutions Float Held111.57%
Institutional HolderSharesReport Date
Avoro Capital Advisors LLC5,888,8882026-03-31
Blackrock Inc.5,088,1022026-03-31
Price (T.Rowe) Associates Inc4,574,0302026-03-31
Deep Track Capital, Lp4,106,0672026-03-31
Deerfield Management Company, L.P3,722,1002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRSAclaris Therapeutics, Inc. $3.92 +3.43% -8.88 $547.48M 0.00%
ALMSAlumis Inc. $7.04 +1.06% -1.80 $869.44M 0.00%
ANABAnaptysBio, Inc. $46.59 +0.82% 7.19 $1.38B 0.00%
ARQTArcutis Biotherapeutics, Inc. $26.95 +10.02% 113.95 $3.37B 0.00%
BHVNBiohaven Ltd. $12.19 +2.18% -2.77 $1.84B 0.00%

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (VERA) stock trades at $29.81 with a market capitalization of $2.14B. The stock is valued at a price-to-earnings (P/E) ratio of -5.58, price-to-book of 5.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $23.05 and $56.05, and currently trades 46.8% below its 52-week high.

On profitability, Vera Therapeutics, Inc. generates a return on equity (ROE) of -84.13%, return on capital employed of -85.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.66 +0.77% JNJ Johnson & Johnson $261.06 +1.78% ABBV AbbVie Inc. $277.15 +1.74% MRK Merck & Company, Inc. Common Stock (new) $146.65 +3.00% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.58 +2.06% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $661.61 +1.48% AMGN Amgen Inc. $417.32 +2.42% GILD Gilead Sciences, Inc. $151.12 +2.73% ABT Abbott Laboratories $99.29 +0.81% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides